These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11019440)

  • 21. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
    J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.
    Zhou HY; Zheng YH; Zhang CY; Ding PP; Zou W
    Chin Med J (Engl); 2005 Apr; 118(7):609-11. PubMed ID: 15820096
    [No Abstract]   [Full Text] [Related]  

  • 23. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated mucosal addressin cell adhesion molecule-1 expression in acquired immunodeficiency syndrome is maintained during antiretroviral therapy by intestinal pathogens and coincides with increased duodenal CD4 T cell densities.
    Miao YM; Hayes PJ; Gotch FM; Barrett MC; Francis ND; Gazzard BG
    J Infect Dis; 2002 Apr; 185(8):1043-50. PubMed ID: 11930313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
    J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune restoration disorders following HAART.
    Davaro RE; Himlan PH
    AIDS Read; 1999; 9(3):167-9. PubMed ID: 12728901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.
    Orsilles MA; Pieri E; Cooke P; Caula C
    APMIS; 2006 Jan; 114(1):55-60. PubMed ID: 16499662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV therapeutics, continued: another HIV protease inhibitor approved.
    Laurence J
    AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of anti retroviral therapy (ART) on CD4 T lymphocyte count and the spectrum of opportunistic infections in HIV/AIDS in Manipur.
    Chitra Y; Urgen S; Dayananda I; Brajachand SN
    J Commun Dis; 2009 Mar; 41(1):19-24. PubMed ID: 19886171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
    Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
    Valdez H; Mitsuyasu R; Landay A; Sevin AD; Chan ES; Spritzler J; Kalams SA; Pollard RB; Fahey J; Fox L; Namkung A; Estep S; Moss R; Sahner D; Lederman MM
    J Infect Dis; 2003 Jan; 187(2):320-5. PubMed ID: 12552459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
    J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited immune recovery after treatment with antiretrovirals, IL-2; interview with Clifford Lane, M.D. Interview by John S. James.
    Lane C
    AIDS Treat News; 1997 Jun; (No 272):1-5. PubMed ID: 11364426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.
    McCutchan JA; Wu JW; Robertson K; Koletar SL; Ellis RJ; Cohn S; Taylor M; Woods S; Heaton R; Currier J; Williams PL
    AIDS; 2007 May; 21(9):1109-17. PubMed ID: 17502721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of phenotyping and replication capacity in anti-HIV therapeutics.
    Baliga CS; Sutton RE
    Curr Opin Mol Ther; 2004 Jun; 6(3):308-17. PubMed ID: 15264434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.